HOUSTON--(BUSINESS WIRE)--A recent in vitro study by the Dutch company OrgaNext Research demonstrates that addition of vitamin D to nandrolone not only synergistically stimulates the proliferation of skeletal muscle stem cells, but also improves the safety profile of nandrolone.
OrgaNext Research is developing NDD, a new medicine combining nandrolone decanoate and vitamin D3 to support the recovery of elderly patients after hip fractures.
Each year 310.000 people in the United States and almost 800.000 people in Europe suffer from hip fractures and these numbers are expected to increase as the population ages. Hip fractures are a persistent cause of excessive morbidity, reduced life quality, and premature mortality among older people. Among survivors, 50% need assistance to walk and 90% need assistance to climb stairs after 1 year. Among women who lived independently before hip fracture, about half remain in long term care or need help with the activities of daily living one year after the event. Currently there is no drug intervention therapy available to address the debilitating consequences of slow and/or partial recovery of hip fracture patients.
OrgaNext Research tested the in vitro effects of the addition of vitamin D to nandrolone in human prostate cells, a model that is used to test undesired androgenic effects. They demonstrated that addition of vitamin D to nandrolone inhibits unwanted cell proliferation and therefore likely will improve the safety profile of nandrolone. The Dutch scientist Lenus Kloosterboer, PhD, will presents these data during the Annual Meeting of the Endocrine Society (June 23-26) in Houston, Texas.
Kloosterboer: “Previously we demonstrated that the active metabolites of both vitamin D and nandrolone stimulate expression of their own and each other's receptors in human skeletal muscle and that proliferation of muscle stem cells is synergistically stimulated by both compounds. Now we found that addition of 1α,25-dihydroxyvitamin D3, the active metabolite of vitamin D3, to nandrolone reduces the androgenic activity of nandrolone in vitro. We expect that the combination is likely to have less androgenic side effects than nandrolone alone. We are very excited by these findings, because they hold the promise that we indeed can develop a low dose safe and effective therapy to help elderly patients to recover after hip fracture. The results of this study bring us closer to offering a clinical solution. Later this year we hope to start with our first in human studies with NDD.”
About OrgaNext Research
OrgaNext Research BV is a privately owned Dutch biopharmaceutical company focused on the development of medicines that help people to recover physical strength after hospitalization and injury. More information: http://www.organext.com.